상세 보기
Safety results in Asian participants (pts) from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for pts with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis
- Hong, J. Y.;
- Rimassa, L.;
- Chan, S. L.;
- Sangro, B.;
- Kelley, R. K.;
- 외 11명
Citations
WEB OF SCIENCE
0Citations
SCOPUS
0- 제목
- Safety results in Asian participants (pts) from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for pts with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis
- 저자
- Hong, J. Y.; Rimassa, L.; Chan, S. L.; Sangro, B.; Kelley, R. K.; Kim, J. H.; Ryu, M. H.; Chon, H. J.; Tada, F.; Choi, H. J.; Sasaki, M.; Walsh, R. J.; Li, Q.; Sun, P.; Baur, B.; Kudo, M.
- 발행일
- 2025-12
- 유형
- Meeting Abstract
- 권
- 36